ASCO 2021 | 80mg regorafenib plus pembrolizumab for 1L HCC

Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents updated results from a Phase Ib study of regorafenib 80mg/day or 120mg/day plus pembrolizumab for first-line (1L) treatment of advanced hepatocellular carcinoma (HCC). In this update, first-line regorafenib plus immune checkpoint blockade in advanced HCC demonstrated no new safety signals and encouraging anti-tumor activity. The regorafenib 80mg cohort had lower rates of dose reductions and interruptions due to treatment-related adverse events versus regorafenib 120mg. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.